Anti-Mouse TER-119 (Erythroid Cells) - Recombinant in vivo Functional Grade

Referência T712-5

Tamanho : 5mg

Marca : Leinco Technologies

Contactar o distribuidor local :


Telefone : +1 850 650 7790

AntiMouse TER119 (Erythroid Cells) – Recombinant in vivo Functional Grade

Product No.: T712

[product_table name="All Top" skus="T651"]

Product No.T712
Clone
Ter119
Target
TER119
Product Type
Recombinant Monoclonal Antibody
Alternate Names
Ly76
Isotype
Rat IgG2b κ
Applications
FA
,
FC
,
in vivo

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Immunogen
Fetal liver cells from a C57BL/6 mouse
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multistep process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 28°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ 70°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
FC,
FA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
TER119 activity is directed against mouse Ter119.
Background
TER119 recognizes a 52 kDa cell surface protein that strongly associates with glycophorin A on the erythrocyte membrane 1 . The antigen is not present on a number of tested cell lines, including T cell, B cell, macrophage, mast cell, fibroblast, epithelial, and murine erythroleukemia cultured lines.

TER119 is a mouse erythroid lineagespecific rat monoclonal antibody that reacts with 100% of mature erythrocytes and 8090% of day 14 fetal liver cells, after which the percentage of TER119+ fetal cells declines to 4050% 2. Additionally, TER119 stains 2025% of adult mouse bone marrow cells and 23% of spleen cells, but not thymocytes or lymph node cells.

TER119 was produced in Wister rats immunized with BALB/c fetal liver cells 1 . Spleen cells were fused with X63.Ag8.653 myeloma cells to produce a hybridoma clone reactive against fetal liver cells. TER119 recognizes a 7,9 diOacetyl sialic acid glycoepitope 3 . Additionally, the epitope is sensitive to hemagglutinin esterase derived from bovine coronavirus (Mebus strain) but not influenza C.

Antigen Distribution
TER119 is highly specific for erythroid cells, from early proerythroblasts to mature erythrocytes. TER119 antigen is expressed on normal erythroid cells, but not erythroleukemia cells, even when induced with dimethylsulfoxide. TER119 is not thought to interact with pluripotent hematopoietic stem cells in adult bone marrow.
NCBI Gene Bank ID
Research Area
Immunology

References & Citations

1 Kina T, Ikuta K, Takayama E, et al. Br J Haematol. 109(2):280287. 2000.
2 Ikuta K, Kina T, MacNeil I, et al. Cell. 62(5):863874. 1990.
3 Mahajan VS, Alsufyani F, Mattoo H, et al. Glycobiology. 29(3):222228. 2019.
4 Otani T, Nakamura S, Inoue T, et al. Exp Hematol. 32(7):607613. 2004.
5 Brendt P, Rehfeld I, Kamphausen A, et al. Anaesthesia. 67(5):493500. 2012.
6 Kimball A, Schaller M, Joshi A, et al. Arterioscler Thromb Vasc Biol. 38(5):11021114. 2018.
7 Juban G, Sakakini N, Chagraoui H, et al. Haematologica. 106(4):11061119. 2021.
8 PerikZavodskaia O, PerikZavodskii R, Nazarov K, et al. Int J Mol Sci. 24(21):15752. 2023.
9 Mqadmi A, Abramowitz S, Zheng X, et al. Immunohematology. 22(1):114. 2006.
10 Kumon K, Afify SM, Hassan G, et al. Sci Rep. 11(1):23977. 2021.